{"aliases":[{"type":"Synonym","name":"anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody"},{"type":"Abbreviation","name":"MDX-CTLA-4"},{"type":"LexicalVariant","name":"MDX-CTLA4"},{"type":"Synonym","name":"monoclonal antibody CTLA-4"},{"type":"CodeName","name":"MDX-010"},{"type":"Synonym","name":"MOAB CTLA-4"},{"type":"INDCode","name":"10200"},{"type":"NSCNumber","name":"720801"},{"type":"USBrandName","name":"Yervoy"},{"type":"CodeName","name":"BMS-734016"},{"type":"CodeName","name":"IBI310"},{"type":"Synonym","name":"ipilimumab biosimilar CS1002"},{"type":"CASRegistryName","name":"477202-00-9"}],"definition":{"html":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","text":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/ipilimumab","text":"Ipilimumab"},"nciConceptId":"C2654","nciConceptName":"Ipilimumab","termId":38447,"name":"ipilimumab","firstLetter":"i","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"ipilimumab"}